- Home
- MYGN vs BXC Comparison
MYGN vs BXC Comparison
Compare MYGN & BXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- BXC
- Stock Information
- Founded
- MYGN 1991
- BXC 2004
- Country
- MYGN United States
- BXC United States
- Employees
- MYGN N/A
- BXC N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- BXC Wholesale Distributors
- Sector
- MYGN Health Care
- BXC Consumer Discretionary
- Exchange
- MYGN Nasdaq
- BXC Nasdaq
- Market Cap
- MYGN 642.0M
- BXC 574.9M
- IPO Year
- MYGN 1995
- BXC 2004
- Fundamental
- Price
- MYGN $8.33
- BXC $72.63
- Analyst Decision
- MYGN Hold
- BXC Strong Buy
- Analyst Count
- MYGN 13
- BXC 3
- Target Price
- MYGN $13.50
- BXC $91.00
- AVG Volume (30 Days)
- MYGN 959.5K
- BXC 69.2K
- Earning Date
- MYGN 11-04-2025
- BXC 11-04-2025
- Dividend Yield
- MYGN N/A
- BXC N/A
- EPS Growth
- MYGN N/A
- BXC N/A
- EPS
- MYGN N/A
- BXC 3.42
- Revenue
- MYGN $832,900,000.00
- BXC $2,947,258,000.00
- Revenue This Year
- MYGN $0.06
- BXC $1.54
- Revenue Next Year
- MYGN $5.68
- BXC $4.30
- P/E Ratio
- MYGN N/A
- BXC $21.26
- Revenue Growth
- MYGN 3.83
- BXC N/A
- 52 Week Low
- MYGN $3.76
- BXC $63.14
- 52 Week High
- MYGN $22.92
- BXC $134.79
- Technical
- Relative Strength Index (RSI)
- MYGN 64.16
- BXC 47.74
- Support Level
- MYGN $7.68
- BXC $71.36
- Resistance Level
- MYGN $8.25
- BXC $73.69
- Average True Range (ATR)
- MYGN 0.38
- BXC 2.45
- MACD
- MYGN -0.01
- BXC 0.30
- Stochastic Oscillator
- MYGN 78.80
- BXC 55.45
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About BXC Bluelinx Holdings Inc.
BlueLinx Holdings Inc is engaged in the wholesale distribution of residential and commercial building products. Its business products are split into two categories: Structural products include items such as lumber, plywood, oriented strand board, rebar, and remesh and Specialty products include items such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products. The company's operations are carried out throughout the United States.